Berger Montague investigates potential fiduciary breaches and channel-stuffing at ADMA Biologics
AI Summary- Berger Montague announced an investigation into ADMA Biologics’ board and potential fiduciary-duty breaches.
- ADMA’s flagship product ASCENIV faces declining demand, while the alleged conduct involved revenue growth.
- Berger Montague has operated for more than 55 years and recovered over $50 billion for clients.